- cafead   Nov 03, 2020 at 11:02: AM
via Bristol Myers Squibb’s deucravacitinib has outperformed Amgen’s Otezla in a phase 3 clinical trial of patients with moderate to severe plaque psoriasis. The study linked deucravacitinib to improvements in symptom severity against two measures that served as the co-primary endpoints.
article source
article source